Published in J Urol on July 01, 2003
Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol (2006) 1.48
Lymph node density in oral cavity cancer: results of the International Consortium for Outcomes Research. Br J Cancer (2013) 1.06
Lymph node dissection in bladder cancer: Where do we stand? World J Urol (2015) 1.01
Can neutrophil-lymphocyte ratio and lymph node density be used as prognostic factors in patients undergoing radical cystectomy? ScientificWorldJournal (2013) 0.99
The role of lymph node density in bladder cancer prognostication. World J Urol (2008) 0.88
Lymphovascular invasion in radical cystectomy specimen: is it an independent prognostic factor in patients without lymph node metastases? World J Urol (2009) 0.86
Does the greater number of lymph nodes removed during standard lymph node dissection predict better patient survival following radical cystectomy? World J Urol (2011) 0.84
Role of pelvic lymphadenectomy in the treatment of bladder cancer: a mini review. Korean J Urol (2010) 0.83
Status of robotic cystectomy in 2005. World J Urol (2006) 0.83
Lymph node ratio as a predictor of outcome in patients with oropharyngeal cancer. Eur Arch Otorhinolaryngol (2013) 0.81
Long-term oncologic outcomes after radical cystectomy for bladder cancer at a single institution. J Korean Med Sci (2014) 0.79
Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology (2008) 0.79
Lymph node density as a prognostic variable in node-positive bladder cancer: a meta-analysis. BMC Cancer (2015) 0.79
Lymphadenectomy in management of invasive bladder cancer. Int J Surg Oncol (2011) 0.78
Pelvic lymphadenectomy in the treatment of invasive bladder cancer: literature review. Adv Urol (2011) 0.78
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol (2008) 0.78
Lymph node metastasis mapping in extended lymphadenectomy to the level of the inferior mesenteric artery for bladder cancer. Int J Clin Oncol (2011) 0.78
How close are we to establishing standards of lymphadenectomy for invasive bladder cancer? Ther Adv Urol (2009) 0.77
Role of lymphadenectomy for invasive bladder cancer. Can Urol Assoc J (2009) 0.77
Open versus robotic radical cystectomy with intracorporeal Studer diversion. JSLS (2015) 0.77
Risk stratification of oral cancer patients using a combined prognostic factor including lymph node density and biomarker. J Cancer Res Clin Oncol (2011) 0.77
Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter. Adv Urol (2009) 0.77
Role of lymph node dissection in management of bladder cancer. Int J Clin Oncol (2011) 0.77
Extent of lymphadenectomy in radical cystectomy for bladder cancer. World J Surg Oncol (2005) 0.77
A greater number of dissected lymph nodes is associated with more favorable outcomes in bladder cancer treated by radical cystectomy: a meta-analysis. Oncotarget (2016) 0.76
Outcome following radical cystectomy and bladder-preservation therapy in patients with invasive carcinoma of urinary bladder. Indian J Urol (2008) 0.75
Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract. Cancer (2017) 0.75
Extended pelvic lymph node dissection: before or after radical cystectomy? A multicenter study of the Turkish society of urooncology. Korean J Urol (2012) 0.75
Update on the management of invasive bladder cancer 2012. Cancer Manag Res (2012) 0.75
Lymph node density predicts recurrence and death after inguinal lymph node dissection for penile cancer. Investig Clin Urol (2017) 0.75
Extent of pelvic lymph node dissection during radical cystectomy: is bigger better? Rev Urol (2014) 0.75
Differences in histopathological evaluation of standard lymph node dissections result in differences in nodal count but not in survival. World J Urol (2012) 0.75
Oncologic Outcomes and Predictive Factors for Recurrence Following Robot-Assisted Radical Cystectomy for Urothelial Carcinoma: Multicenter Study from Korea. J Korean Med Sci (2017) 0.75
Lymph node density in muscle-invasive transitional cell carcinoma of the urinary bladder; De novo versus progressive disease. Int J Health Sci (Qassim) (2017) 0.75
Seeking a standard for adequate pathologic lymph node staging in primary bladder carcinoma. Virchows Arch (2014) 0.75
Clinical prognosticators of survival in patients with urothelial carcinoma of the bladder and lymph node metastases after cystectomy with curative intent. World J Urol (2014) 0.75
[Standards and perspectives in diagnosis and therapy of bladder carcinoma]. Urologe A (2006) 0.75
Do pure squamous cell carcinomas and urothelial carcinomas have similar prognosis after radical cystectomy? World J Urol (2012) 0.75
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol (2004) 4.09
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res (2010) 3.61
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol (2011) 3.59
Zero ischemia anatomical partial nephrectomy: a novel approach. J Urol (2012) 2.99
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol (2007) 2.83
Critical role of the stress chaperone GRP78/BiP in tumor proliferation, survival, and tumor angiogenesis in transgene-induced mammary tumor development. Cancer Res (2008) 2.81
Face, content and construct validity of a novel robotic surgery simulator. J Urol (2011) 2.66
Benign retroperitoneal schwannoma: a case series and review of the literature. Urology (2003) 2.62
End-Stage Heart Failure With COVID-19: Strong Evidence of Myocardial Injury by 2019-nCoV. JACC Heart Fail (2020) 2.57
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol (2004) 2.50
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol (2011) 2.14
p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer. J Clin Oncol (2007) 2.14
MicroRNA cluster 302-367 enhances somatic cell reprogramming by accelerating a mesenchymal-to-epithelial transition. J Biol Chem (2011) 2.08
"Trifecta" in partial nephrectomy. J Urol (2012) 2.03
Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol (2006) 2.01
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol (2004) 2.00
GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res (2006) 1.96
Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol (2006) 1.92
A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics (2004) 1.88
The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res (2010) 1.85
Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. Eur Urol (2009) 1.79
Glucose-regulated protein GRP78 is up-regulated in prostate cancer and correlates with recurrence and survival. Hum Pathol (2007) 1.74
Radical cystectomy with extended lymphadenectomy: evaluating separate package versus en bloc submission for node positive bladder cancer. J Urol (2007) 1.74
Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer. Clin Cancer Res (2006) 1.73
Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst (2002) 1.72
Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res (2004) 1.71
Lymph node dissection technique is more important than lymph node count in identifying nodal metastases in radical cystectomy patients: a comparative mapping study. Eur Urol (2011) 1.65
FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest (2013) 1.65
Long-term outcomes of open radical retropubic prostatectomy for clinically localized prostate cancer in the prostate-specific antigen era. Urology (2012) 1.58
Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun (2013) 1.57
Molecular determinants of cetuximab efficacy. J Clin Oncol (2005) 1.56
Radical cystectomy in the elderly: Comparison of survival between younger and older patients. Cancer (2005) 1.55
Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer (2013) 1.51
Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol (2006) 1.48
Principal component analysis based pre-cystectomy model to predict pathological stage in patients with clinical organ-confined bladder cancer. BJU Int (2012) 1.46
Radical cystectomy for primary neuroendocrine tumors of the bladder: the university of southern california experience. J Urol (2005) 1.45
A novel precision-engineered microfiltration device for capture and characterisation of bladder cancer cells in urine. Eur J Cancer (2013) 1.45
Outcomes of radical cystectomy with extended lymphadenectomy alone in patients with lymph node-positive bladder cancer who are unfit for or who decline adjuvant chemotherapy. BJU Int (2014) 1.44
Does reflux in orthotopic diversion matter? A randomized prospective comparison of the Studer and T-pouch ileal neobladders. World J Urol (2008) 1.44
Natural killer T cells infiltrate neuroblastomas expressing the chemokine CCL2. J Exp Med (2004) 1.43
Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year followup. J Urol (2007) 1.41
A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. Cancer Res (2011) 1.40
Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys (2002) 1.40
Generation of a concise gene panel for outcome prediction in urinary bladder cancer. J Clin Oncol (2009) 1.32
Radical cystectomy in the elderly: comparison of clincal outcomes between younger and older patients. Cancer (2005) 1.28
ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy. Clin Adv Hematol Oncol (2003) 1.27
Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials. Clin Trials (2013) 1.27
Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol (2006) 1.25
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol (2011) 1.25
Role of the spinal cord NR2B-containing NMDA receptors in the development of neuropathic pain. Exp Neurol (2008) 1.24
Temozolomide for treatment-resistant recurrent meningioma. Neurology (2004) 1.23
Differential proteomic analysis of bronchoalveolar lavage fluid in asthmatics following segmental antigen challenge. Mol Cell Proteomics (2005) 1.22
Comparisons of substitution, insertion and deletion probes for resequencing and mutational analysis using oligonucleotide microarrays. Nucleic Acids Res (2005) 1.20
Overexpression of E-cadherin and beta-catenin proteins in metastatic prostate cancer cells in bone. Prostate (2008) 1.19
LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics (2009) 1.17
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy. Sci Rep (2013) 1.16
Salvage radical prostatectomy: quality of life outcomes and long-term oncological control of radiorecurrent prostate cancer. J Urol (2006) 1.16
Comparison of different antibodies for detection of progesterone receptor in breast cancer. Steroids (2002) 1.15
Early complications of cystectomy after high dose pelvic radiation. J Urol (2010) 1.14
Genomic profiling associated with recurrence in patients with rectal cancer treated with chemoradiation. Pharmacogenomics (2006) 1.14
Urethral tumor recurrence following cystectomy and urinary diversion: clinical and pathological characteristics in 768 male patients. J Urol (2005) 1.13
Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J Urol (2005) 1.13
DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics (2009) 1.12
Concurrent and predictive validation of a novel robotic surgery simulator: a prospective, randomized study. J Urol (2011) 1.12
Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res (2005) 1.11